A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma
Status:
Terminated
Trial end date:
2020-06-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and preliminary antitumor activity of
INCB059872 in participants with Ewing sarcoma who are refractory or relapsed from prior
standard therapy and not eligible for further standard systemic therapy.